---
title: "LQIDA's AI Edge Push Drives Hong Kong Small-Cap M&A Surge into Tech, Biotech"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303363689.md"
description: "LQIDA Tech (9611.HK) expands into AI edge computing and data centers, while LeadMind Pharma (2105.HK) advances weight-loss drug trials. Multiple Hong Kong small-caps are pivoting through acquisitions toward technology and biotech, with MicroPort restructuring amid governance challenges."
datetime: "2026-10-28T09:21:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303363689.md)
  - [en](https://longbridge.com/en/news/303363689.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303363689.md)
generator: "portal-rs"
---

# LQIDA's AI Edge Push Drives Hong Kong Small-Cap M&A Surge into Tech, Biotech

Hong Kong small-caps are increasingly channeling capital into technology and biotech pivots, with strategic acquisitions serving as the primary catalyst. LQIDA Tech (9611.HK) finalized its 60% stake acquisition in Suzhou Anruike in late October, establishing a foothold in data center infrastructure while launching a robotics subsidiary for embodied AI data collection. LeadMind Pharma (2105.HK) reported positive 24-week trial results for its weight-loss drug LAE102, showing consistent muscle gain and fat reduction without severe adverse events.

Gotech Fiber (9963.HK) allocated CNY 250 million to acquire optical fiber preform assets, shifting its upstream business contribution from 8.85% to nearly 60% of total revenue. AiLife International (0784.HK) completed its rebranding under HaploX ownership to focus on genetic testing, while GenSea Medical (2225.HK) saw its minimally invasive surgical solutions grow to 74.73% of revenue, attracting sustained southbound capital inflows.

Traditional sectors show divergent trajectories. 361 Degrees (1361.HK) maintained its 8%-10% full-year revenue guidance amid robust Southeast Asian expansion, while ChipSMT (0365.HK) navigated SMT equipment headwinds through energy business stabilization. MicroPort Medical (0853.HK) remains suspended for over two months amid lease dispute investigations, with new management implementing governance reviews. Crayon Shin-chan Food (1262.HK) posted wider losses following Qucloud acquisition, as Yuehua Entertainment (2306.HK) explores AI-driven entertainment through VR music films.

### Related Stocks

- [01361.HK](https://longbridge.com/en/quote/01361.HK.md)
- [00853.HK](https://longbridge.com/en/quote/00853.HK.md)
- [00365.HK](https://longbridge.com/en/quote/00365.HK.md)
- [01262.HK](https://longbridge.com/en/quote/01262.HK.md)
- [02306.HK](https://longbridge.com/en/quote/02306.HK.md)
- [09611.HK](https://longbridge.com/en/quote/09611.HK.md)
- [00784.HK](https://longbridge.com/en/quote/00784.HK.md)
- [09963.HK](https://longbridge.com/en/quote/09963.HK.md)
- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)
- [02225.HK](https://longbridge.com/en/quote/02225.HK.md)

## Related News & Research

- [Law Kiong Holdings Raises Stake in BLD Plantation to 6.816%](https://longbridge.com/en/news/305948439.md)
- [Shanghai Longcheer Files Next-Day Return to HKEX Disclosing Share Buyback](https://longbridge.com/en/news/305661056.md)
- [Shanghai Longcheer Technology Files HKEX Next-Day Disclosure Return Announcing Share Buyback](https://longbridge.com/en/news/305944059.md)
- [Laekna's Oral Obesity Drug LAE124 Reduces Body Weight in Rat Studies](https://longbridge.com/en/news/305249102.md)
- [Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist](https://longbridge.com/en/news/305249268.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**